Quantum Biopharma (QNTM) Current Deferred Revenue (2024 - 2025)
Quantum Biopharma recorded quarterly Current Deferred Revenue of -$1.0 million in Q2 2025, down 200.0% quarter-over-quarter from $1.0 million in Q1 2025.
Quantum Biopharma's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at -$1.0 million for Q2 2025.
- In Q2 2025, Current Deferred Revenue changed N/A year-over-year to -$1.0 million; the TTM figure through Jun 2025 stood at -$1.0 million (changed N/A YoY), while the FY2024 annual figure was $1.0 million, changed N/A from the prior year.
- Current Deferred Revenue came in at -$1.0 million for Q2 2025 at Quantum Biopharma, down from $1.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q4 2024 to a low of -$1.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |